Celgene Corporation - Contingent Value Right (CELGZ)

0.14 12.17
Prev Close 1.15
Open 1.12
Day Low/High 0.99 / 1.12
52 Wk Low/High 0.92 / 2.50
Volume 18.50K
Exchange NASDAQ
Div & Yield N.A. (N.A)

Celgene Notified Of ANDA Filing For ABRAXANE®

Celgene Corporation (NASDAQ: CELG, CELGZ) today announced it has received a Paragraph IV Notice Letter advising that Actavis LLC submitted an Abbreviated New Drug Application (ANDA) to the U.

Celgene's Abraxane: Two Month Survival Boost In Pancreatic Cancer Trial

New details were released Tuesday from the phase III study of Celgene's Abraxane in pancreatic cancer.

Celgene: Abraxane Boosts Pancreatic Cancer Survival

Expanding use of Abraxane into pancreatic cancer could net Celgene another $1 billion in revenue.

Celgene Surprises With Melanoma Drug Study Victory

Celgene's Abraxane delays tumor growth in patients with advanced melanoma.

Celgene's Abraxane Is Talk of European Cancer Confab

A study of Abraxane in pancreatic cancer generates a ton of buzz even with data still weeks away.

Celgene CVR: Upside Into Abraxane Pancreatic Cancer Trial Data

How best to invest in the next important clinical trial catalyst facing Celgene.